Dr. Jianchun Duan 段建春
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Multidisciplinary and individualized treatment for thoracic tumors, especially lung cancer. Expertise in bronchoscopic diagnosis and treatment, chemotherapy, molecular targeted therapy, and biomarker-guided personalized care.
Dr. Duan holds a master’s degree from West China Medical Center (2004) and a PhD in Oncology from Peking University Health Science Center (2011). Promoted to Associate Chief Physician in 2012 and currently Chief Physician. Dr. Duan has participated in over 10 multicenter clinical trials and received awards including the Ministry of Education Science and Technology Award (Second Class) and the Chinese Medical Award (Third Class).
Name order: in Chinese the family name comes first (Duan Jianchun). Papers usually list the name as Jianchun Duan or Duan J.
Selected publications
135 papers on PubMed matched by name and affiliation; 31 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2026 (senior author): Global burden of respiratory infections and tuberculosis and risk factors, 1990-2021: a systematic analysis of the Global Burden of Disease Study 2021. PubMed 42996967
- Chin Med J (Engl), 2026 (senior author): Different genetic associations of chronic lung diseases and lung cancer risk in European and East Asian populations. PubMed 42619367
- Adv Ther, 2026 (first author): Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study. PubMed 42667570
- BMC Pulm Med, 2026 (senior author): Prognostic significance of CEP55 expression in non-small cell lung cancer: a systematic review and meta-analysis. PubMed 42001102
- Cancer Cell, 2026 (first author): HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial. PubMed 41791381
- CA Cancer J Clin, 2026 (first author): Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. PubMed 41818162
- Innovation (Camb), 2026 (first author): Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study. PubMed 41737326
- Lung Cancer, 2025 (senior author): Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial. PubMed 41124837
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion